Revvity (RVTY) Q3 2026 Earnings Call Transcript

Revvity reported Q3 pro forma organic revenue growth of 7%, adjusted operating margin of 29.4%, and adjusted EPS of $1.37, which was $0.08 above the midpoint of expectations; Life Sciences grew 9% and Diagnostics 5%. Management raised full-year organic growth guidance to approximately 5% from 4%–5%, adjusted EPS guidance to $5.40–$5.45, and operating margin guidance to 28.8%. Management cited improving pharma and biotech demand and early AI-related demand across a broader range of products, while noting China reproductive-health pressures and a 160-basis-point Diagnostics margin headwind from the China immunodiagnostics business planned for divestiture.

Analysis

The key positive is not the AI narrative by itself; it is the possibility that normalized pharma/biotech spending and AI-driven data needs reinforce each other. That would lift utilization across instruments and consumables, with recurring reagents revenue potentially providing a more durable read-through than lumpy platform shipments. But Q3 included a disclosed timing contribution from bulk screening orders, and management expects software growth to moderate in Q4. Do not annualize the quarter: the 5% full-year organic outlook is a better near-term anchor until backlog converts into repeat orders.

For the next several weeks, the Nov. 13 Investor Day is the catalyst: look for measurable adoption, customer conversion, and a 2027 growth framework, not a broader AI addressable-market story. Over 6–18 months, structural efficiency could support earnings even if demand growth moderates; the counter-risk is that operating leverage reverses if instruments or reagent demand stalls. The China immunodiagnostics divestiture may remove a segment-margin drag, but timing and proceeds are unverified and should not be capitalized in advance. China reproductive-health pressure appears limited at the consolidated level based on the stated revenue exposure.

Contrarian risk: a good quarter may be conflated with an AI-led inflection before the company has quantified AI-related revenue. Broad-based end-market recovery also benefits established life-science tools competitors, so Revvity’s outperformance needs to persist to justify a differentiated premium. The Sanofi assay collaboration is not, on the information provided, a material near-term Sanofi earnings catalyst.

Key Decisions for Investors

• RVTY: Favor a staged long on post-results weakness rather than chasing strength into the Nov. 13 Investor Day. Reassess on evidence of expanding instrument backlog converting to revenue and sustained reagent growth; reduce or exit if Q4 organic growth falls short of the approximately 5% outlook or management signals weaker 2027 demand.
• Treat AI as an upside option, not the base case in forecasts. At Investor Day, require evidence such as product uptake, customer expansion, or quantified recurring software economics before assigning meaningful incremental value to new Signals offerings.
• Monitor Q4 reagent growth against the expected mid-single-digit pace and Signals growth against management’s moderated mid-teens outlook. Weakness in both would suggest Q3 strength was more timing- and mix-driven than a durable demand acceleration.
• Keep Sanofi (SNY) on watch, not as a trade: the early-childhood screening collaboration may have strategic value, but no scale, economics, or near-term revenue contribution is established here.